Biosimilars present a range of challenges to both regulators and HTA entities. The number that are available on markets worldwide still is low, which means that experience with their assessment is limited. OHE convened a one-day roundtable specifically to discuss whether and how biosimilars should be evaluated from a health economics perspective. Download a summary of that discussion here with this OHE Briefing. (Source: Office of Health Economics, 4/9/14).
You are here: / / Should Biosimilar Medicines Be Subject To HTA Processes